ECSP13012392A - Cristal de compuesto de amida - Google Patents

Cristal de compuesto de amida

Info

Publication number
ECSP13012392A
ECSP13012392A ECSP13012392A ECSP13012392A EC SP13012392 A ECSP13012392 A EC SP13012392A EC SP13012392 A ECSP13012392 A EC SP13012392A EC SP13012392 A ECSP13012392 A EC SP13012392A
Authority
EC
Ecuador
Prior art keywords
crystal
amida
ylcarbonyl
methoxybutyl
morpholin
Prior art date
Application number
Other languages
English (en)
Inventor
Masato Kitayama
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP13012392A publication Critical patent/ECSP13012392A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un cristal de clorhidrato de 1-(4-metoxibutil)-N-(2-metilpropil)-N-[(3S,5R)-5-(morfolin-4-ilcarbonil)piperidin-3-il]-1H-bencimidazol-2-carboxamida que tiene excelente actividad inhibitoria de renina que es útil como un conservador u otro agente terapéutico para tipos de disfunción de órganos y similares, que se derivan de alta presión sanguínea e hipertensión. El cristal de clorhidrato de 1-(4-metoxibutil)-N-(2-metilpropil)-N-[(3S,5R)-5-(morfolin-4-ilcarbonil)piperidin-3-il]-1H-bencimidazol-2-carboxamida tiene un patrón de difracción de rayos-X de polvo, en donde el espaciamiento de celosía (d) del patrón de difracción de rayos-X de polvo, tiene picos característicos que aparecen en los alrededores de 26.43 ± 0.2, 7.62 ± 0.2 y 4.32 ± 0.2 angstroms.
ECSP13012392 2010-06-16 2013-01-16 Cristal de compuesto de amida ECSP13012392A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010137194 2010-06-16

Publications (1)

Publication Number Publication Date
ECSP13012392A true ECSP13012392A (es) 2013-03-28

Family

ID=45348277

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012392 ECSP13012392A (es) 2010-06-16 2013-01-16 Cristal de compuesto de amida

Country Status (27)

Country Link
US (1) US9018374B2 (es)
EP (1) EP2583967B1 (es)
JP (1) JP5782438B2 (es)
KR (1) KR20130119903A (es)
CN (1) CN103068816B (es)
AU (1) AU2011266099B2 (es)
BR (1) BR112012032055B8 (es)
CA (1) CA2802483C (es)
CL (1) CL2012003526A1 (es)
CO (1) CO6670573A2 (es)
DO (1) DOP2012000313A (es)
EA (1) EA022094B1 (es)
EC (1) ECSP13012392A (es)
ES (1) ES2524896T3 (es)
GE (1) GEP20146195B (es)
HK (1) HK1179605A1 (es)
IL (1) IL223562A (es)
MA (1) MA34378B1 (es)
MX (1) MX2012014828A (es)
MY (1) MY163927A (es)
PE (1) PE20130283A1 (es)
SG (1) SG186223A1 (es)
TN (1) TN2012000589A1 (es)
TW (1) TWI511967B (es)
UA (1) UA108888C2 (es)
WO (1) WO2011158880A1 (es)
ZA (1) ZA201300065B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107879941A (zh) * 2012-02-14 2018-04-06 陶氏环球技术有限责任公司 非离子型表面活性剂组合物
EP2814466B1 (en) * 2012-02-15 2018-12-26 Takeda Pharmaceutical Company Limited Tablet comprising 1-(4-methoxybutyl)-n-(2-methylpropyl)-n-[(3s,5r)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1h-benzimidazole-2-carboxamide or a salt thereof
CN103831159B (zh) * 2014-01-20 2016-04-13 华润赛科药业有限责任公司 一种阿齐沙坦微粉化方法
EP3130581A4 (en) * 2014-04-10 2017-11-22 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
GB2542876B (en) * 2015-04-20 2019-10-23 Johnson Matthey Plc Structure Directing Agent
CN107595853A (zh) * 2017-10-25 2018-01-19 桂林浩新科技服务有限公司 一种用于治疗高血压合并冠心病的药物组合物及其用途
CN107595842A (zh) * 2017-10-25 2018-01-19 桂林浩新科技服务有限公司 一种药物复方制剂及在制备治疗高血压合并冠心病的药物中的用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1302462A4 (en) 2000-07-17 2007-07-18 Takeda Pharmaceutical Sulphonic derivatives, process for their preparation and their use
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
PE20040609A1 (es) 2002-11-01 2004-10-29 Takeda Pharmaceutical Compuestos heterociclicos aromaticos como promotores de un factor neurotrofico
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
JP3618341B2 (ja) * 2003-04-15 2005-02-09 山之内製薬株式会社 臭化物及びその結晶
US20060223831A1 (en) 2003-04-15 2006-10-05 Isao Kinoyama Bromide and its crystal
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
AU2004247615B2 (en) 2003-06-18 2008-02-21 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as CB1 modulators
WO2005030740A1 (ja) 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited チアゾリン誘導体およびその用途
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
RU2006126978A (ru) 2003-12-25 2008-01-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 3-(4-бензилоксифенил)пропановой кислоты
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
WO2005095338A1 (ja) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
JP5094394B2 (ja) 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
US20090208584A1 (en) 2005-06-09 2009-08-20 Tomohiro Yoshinari Solid preparation
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
WO2007013694A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited フェノキシアルカン酸化合物
WO2007013689A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited シクロプロパンカルボン酸化合物
CN101282725A (zh) 2005-08-10 2008-10-08 武田药品工业株式会社 糖尿病治疗剂
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
RS52307B (en) 2006-06-27 2012-12-31 Takeda Pharmaceutical Company Limited CONDENSED CYCLIC UNITS
JP5306818B2 (ja) 2006-10-18 2013-10-02 武田薬品工業株式会社 縮合複素環化合物
US7652133B2 (en) 2006-10-19 2010-01-26 Takeda Pharmaceutical Company Limited Indole compound
US20100016396A1 (en) 2007-01-29 2010-01-21 Hiroshi Imoto Pyrazole compound
AU2008215490A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素５員複素環化合物
US20110301155A1 (en) 2007-06-19 2011-12-08 Tsuneo Yasuma Indazole compounds for activating glucokinase
JP2010229034A (ja) 2007-07-26 2010-10-14 Dainippon Sumitomo Pharma Co Ltd 二環性ピロール誘導体
PT2297114T (pt) 2008-06-19 2018-07-26 Takeda Pharmaceuticals Co Composto heterocíclico e a sua utilização
JP4901849B2 (ja) 2008-12-15 2012-03-21 バブコック日立株式会社 空気清浄機、及び分析室、並びに空気の浄化方法
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity

Also Published As

Publication number Publication date
ZA201300065B (en) 2014-03-26
SG186223A1 (en) 2013-01-30
CN103068816B (zh) 2015-01-07
EP2583967A1 (en) 2013-04-24
CO6670573A2 (es) 2013-05-15
KR20130119903A (ko) 2013-11-01
CA2802483C (en) 2017-10-24
TW201206914A (en) 2012-02-16
BR112012032055B8 (pt) 2019-11-12
UA108888C2 (xx) 2015-06-25
EP2583967B1 (en) 2014-10-01
EP2583967A4 (en) 2013-09-04
CL2012003526A1 (es) 2013-05-31
ES2524896T3 (es) 2014-12-15
CN103068816A (zh) 2013-04-24
GEP20146195B (en) 2014-11-10
CA2802483A1 (en) 2011-12-22
US20130090337A1 (en) 2013-04-11
EA022094B1 (ru) 2015-10-30
MY163927A (en) 2017-11-15
WO2011158880A1 (ja) 2011-12-22
BR112012032055B1 (pt) 2019-10-22
PE20130283A1 (es) 2013-03-25
BR112012032055A2 (pt) 2016-11-08
JPWO2011158880A1 (ja) 2013-08-19
HK1179605A1 (en) 2013-10-04
US20130252954A2 (en) 2013-09-26
EA201291453A1 (ru) 2013-05-30
MA34378B1 (fr) 2013-07-03
IL223562A (en) 2015-03-31
DOP2012000313A (es) 2013-02-15
JP5782438B2 (ja) 2015-09-24
MX2012014828A (es) 2013-02-27
AU2011266099A1 (en) 2013-01-24
AU2011266099B2 (en) 2014-09-11
TWI511967B (zh) 2015-12-11
US9018374B2 (en) 2015-04-28
TN2012000589A1 (en) 2014-04-01

Similar Documents

Publication Publication Date Title
ECSP13012392A (es) Cristal de compuesto de amida
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
UY38160A (es) Partículas implantables y métodos relacionados
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
CL2008002998A1 (es) Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion.
NI201600037A (es) Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso.
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
UY30107A1 (es) Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
AR069886A1 (es) Formas cristalinas de n-(terc-butoxicarbonil)-3-metil-l-valil-(4r)-4-((7-cloro-4-metoxi-1-isoquinolinil)oxi)-n-((1r,2s)-1-((ciclopropilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida
CR20120345A (es) Derivados de 3-hidroxi-5-arilisotiazol novedosos
PE20140040A1 (es) Composicion farmaceutica que comprende un inhibidor de la actividad de mek
UY31554A1 (es) Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus
NI201000051A (es) Benzotiazoles como moduladores del receptor de grelina.
ECSP17059323A (es) Formulacion de combinacion de tesofensina y betabloqueante
PE20170470A1 (es) Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdidad de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes
ECSP19077969A (es) Compuesto heterociclico
PE20140123A1 (es) Formas cristalinas de la sal clorhidrato de (4a-r,9a-s)-1-(1h-benzoimidazol-5-carbonil)-2,3,4,4a,9,9a-hexahidro-1h-inden[2,1-b]piridin-6-carbonitrilo y su uso como inhibidores de hsd 1
ECSP17038455A (es) Combinaciones de compuestos activos
PE20190150A1 (es) 6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORyT
MX2020004491A (es) Preparacion externa para tratar tinea unguium.
UY36447A (es) Combinaciones de compuestos activos
CL2011002045A1 (es) Compuesto derivado de n-[(3e)-5-(cicloalquilamino)-5-oxo-1-fenilpent-3-en-2-il]benzamida, utiles en el tratamiento del prurito de causa desconocido o asociado a una enfermedad dermatologica tal como dermatitis atopica, psoriasis, urticaria, entre otras; combinacion farmaceutica.
UY37306A (es) Combinaciones de compuestos activos